Hsbc Holdings PLC Acquires New Shares in BioCryst Pharmaceuticals, Inc. $BCRX

Hsbc Holdings PLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, HoldingsChannel reports. The firm bought 109,320 shares of the biotechnology company’s stock, valued at approximately $1,079,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the last quarter. Allworth Financial LP bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $52,000. Pallas Capital Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at $101,000. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at $77,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth about $103,000. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on BCRX. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target for the company. Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Finally, Wedbush decreased their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $9.70 on Tuesday. The company has a market cap of $2.48 billion, a P/E ratio of -6.47 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The stock’s fifty day moving average price is $9.73 and its 200-day moving average price is $9.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 earnings per share. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.